Last reviewed · How we verify
6-week olanzapine double blind treatment
At a glance
| Generic name | 6-week olanzapine double blind treatment |
|---|---|
| Sponsor | Rene Kahn |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications (PHASE2)
- Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (PHASE3)
- Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia (PHASE3)
- Optimization of Treatment and Management of Schizophrenia in Europe (PHASE4)
- Olanzapine in the Treatment of Patients With Anorexia Nervosa (PHASE2)
- A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia (NA)
- Treatment Resistant Bipolar Depression (PHASE1)
- A Study to Test the Safety and Efficacy of MK-8998 in Acutely Psychotic Participants With Schizophrenia (MK-8998-004) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 6-week olanzapine double blind treatment CI brief — competitive landscape report
- 6-week olanzapine double blind treatment updates RSS · CI watch RSS
- Rene Kahn portfolio CI